Population | n | KDT50 (95% CI) | KRR50 | KDT95 (95% CI) | KRR95 | 24-h mortality (95% CI) |
---|---|---|---|---|---|---|
Lab | 388 | 18.9 (16.8–20.8) | 1.0 | 47.6 (41.7–56.7) | 1.0 | 99.3% (98.4–100%) |
BJ | 348 | 26.0 (23.1–28.7) | 1.4 | 63.8 (54.8–79.0) | 1.3 | 88.0% (84.0–92.0%) |
SJZ | 327 | 30.6 (29.3–31.9) | 1.6 | 74.0 (68.4–81.3) | 1.6 | 60.3% (54.0–66.5%) |
HZ | 362 | 32.8 (30.1–35.7) | 1.7 | 84.8 (72.4–105.6) | 1.8 | 54.8% (48.7–60.8%) |
WH | 343 | 27.7 (26.4–29.0) | 1.5 | 76.2 (69.9–84.4) | 1.6 | 79.8% (74.9–84.8%) |
MS | 305 | 31.2 (29.7–32.7) | 1.7 | 87.4 (79.1–98.6) | 1.8 | 69.4% (63.3–75.4%) |
GZ | 346 | 81.5 (72.4–96.0) | 4.3 | 306.7 (225.5–474.9) | 6.4 | 33.9% (28.0–39.7%) |
ZJ | 424 | 19.8 (17.3–22.2) | 1.0 | 56.2 (48.0–69.8) | 1.2 | 93.5% (90.8–96.2%) |
LS | 460 | 39.9 (35.1–46.2) | 2.1 | 117.7 (88.0–198.5) | 2.5 | 56.8% (51.7–61.9%) |